

Dr Mahavir Prashad joins Sai Life Sciences as VP, Early Phase Process Development

11 February 2021 | News

Dr Prashad is a recognised leader in chemical process R&D and leveraging green chemistry principles and modern technologies in API synthesis. He possesses an excellent scientific track record through 94 publications, 4 review articles, 1 book chapter, 71 patent/applications, and 10 invited lectures at scientific conferences



Sai Life Sciences announced the addition of Dr Mahavir Prashad, an acknowledged scientific leader and industry veteran, to its scientific leadership team as Vice President of Early Phase Process Development. With over three decades of experience in advanced research, and roles of increasing responsibility in one of the world's leading pharmaceutical companies, Dr Prashad will provide impetus to Sai Life Sciences' growing capabilities and help accelerate the drug development programmes of its customers.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We see Early Phase Process Development as a key pivot in compressing the time to market of our clients' drug development programmes. This priority has now received significant momentum with the joining of Dr Mahavir Prashad."

Dr Prashad is a recognised leader in chemical process R&D and leveraging green chemistry principles and modern technologies in API synthesis. He possesses an excellent scientific track record through 94 publications, 4 review articles, 1 book chapter, 71 patent/applications, and 10 invited lectures at scientific conferences. He was awarded Novartis Leading Scientist award in 2002 and also the 2010 Diversity & Inclusion award of the Novartis Pharmaceuticals Corporation. Dr Prashad has a PhD in Organic Chemistry from the Central Drug Research Institute in Lucknow, India and was awarded a Post-Doctoral Research Fellowship at Duke University in North Carolina, US.

Commenting on his appointment, Dr Prashad said, "I am very excited to be joining Sai Life Sciences and its passionate leadership team with a clear Early Phase Development acceleration strategy. I am looking forward to working with talented and dedicated scientists at Sai who are enabling their partners in delivering novel medicines to patients in a speedy and socially responsible manner through science and innovation."

